Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Long MSTR Daily Target ETF vs Stryker Corporation — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $39.84 (market cap $809.00M), while Stryker Corporation trades at $277.29 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 131.3× T-Rex 2X Long MSTR Daily Target ETF's market cap, and Stryker Corporation pays a 1.27% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Long MSTR Daily Target ETF for 18 Days and Stryker Corporation for 21 Days on average.
| MSTU | SYK | |
|---|---|---|
Market Cap | $809.00M | $106.24B |
Volume | 4,577,465 | 2,982,001 |
Sector | Leveraged / Inverse | Health |
52-Week High | $451.00 | $388.35 |
52-Week Low | $14.60 | $269.75 |
Typical Hold Time | 18 Days | 21 Days |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTU trades at $40.50, up 2.66% with a bearish technical signal from moving averages while oscillators remain neutral. The stock faces significant resistance at $41-$43 levels with support at $37-$35. Recent corporate actions include a 10:1 reverse stock split effective August 24, 2026, and a $0.29 dividend declaration for H2-2026.
The leveraged ETF structure presents both opportunity and risk - offering amplified exposure to MSTR but with daily rebalancing that can erode value during volatility. Key risks include the compounding effect of daily leverage and Bitcoin price sensitivity. Investors should monitor the underlying stock's fundamentals and Bitcoin market dynamics closely.
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
